Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer.
Saved in:
| Title: | Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer. |
|---|---|
| Authors: | Jeannot E; Department of Pathology, Institut Curie, Paris and Saint Cloud, France.; Department of Genetics, Institut Curie, Paris and Saint Cloud, France., Latouche A; INSERM U900, Institut Curie, Saint-Cloud, France.; Conservatoire National des Arts et Métiers, Paris, France., Bonneau C; INSERM U900, Institut Curie, Saint-Cloud, France.; Department of Surgery, Institut Curie, PSL Research University, PSL Research University, Paris and Saint-Cloud, France., Calméjane MA; Department of Pathology, Institut Curie, Paris and Saint Cloud, France., Beaufort C; Department Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Ruigrok-Ritstier K; Department Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Bataillon G; Department of Pathology, Institut Curie, Paris and Saint Cloud, France., Larbi Chérif L; Department of Drug Development and Innovation (D3i), Institut Curie, Paris and Saint-Cloud, France., Dupain C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris and Saint-Cloud, France., Lecerf C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris and Saint-Cloud, France., Popovic M; Oncology Institute of Vojvodina, Put doktora Goldmana, Sremska Kamenica, Serbia., de la Rochefordière A; Department of Radiotherapy, Institut Curie, PSL Research University, Paris, France., Lecuru F; Department of Surgery, Institut Curie, PSL Research University, PSL Research University, Paris and Saint-Cloud, France., Fourchotte V; Department of Surgery, Institut Curie, PSL Research University, PSL Research University, Paris and Saint-Cloud, France., Jordanova ES; Department of Obstetrics and Gynecology, Center for Gynaecologic Oncology Amsterdam, location Vumc, Amsterdam UMC and The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., von der Leyen H; Hannover Clinical Trial Center, Hannover Medical School, Hannover, Germany., Tran-Perennou C; Department of Pathology, Institut Curie, Paris and Saint Cloud, France., Legrier ME; DREH, Institut Curie, Paris and Saint Cloud, France emmanuelle.jeannot@curie.fr., Dureau S; DREH, Institut Curie, Paris and Saint Cloud, France., Raizonville L; DREH, Institut Curie, Paris and Saint Cloud, France., Bello Roufai D; Department of Drug Development and Innovation (D3i), Institut Curie, Paris and Saint-Cloud, France., Le Tourneau C; INSERM U900, Institut Curie, Saint-Cloud, France.; Department of Drug Development and Innovation (D3i), Institut Curie, Paris and Saint-Cloud, France.; Paris-Saclay University, Paris, France., Bièche I; Department of Genetics, Institut Curie, Paris and Saint Cloud, France., Rouzier R; INSERM U900, Institut Curie, Saint-Cloud, France.; Department of Surgery, Institut Curie, PSL Research University, PSL Research University, Paris and Saint-Cloud, France., Berns EMJJ; Department Medical Oncology, Erasmus MC, Rotterdam, the Netherlands., Kamal M; Department of Drug Development and Innovation (D3i), Institut Curie, Paris and Saint-Cloud, France., Scholl S; Department of Drug Development and Innovation (D3i), Institut Curie, Paris and Saint-Cloud, France. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Nov 01; Vol. 27 (21), pp. 5869-5877. Date of Electronic Publication: 2021 Jul 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
